Subscribe

Subscribe

Latest Content

Solar

Storage

Wind

Event Spotlight

BLOGS

DISTRIBUTECH+ RECAP: Energy Storage Utility Case Studies

Webcast

OPINION

RESOURCES

CLARION ENERGY MEDIA

POWER & ENERGY EVENT SERIES

Privacy Policy

Copyright © 2019 - 2021

Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Petros Pharmaceuticals Inc (NQ: PTPI )

0.6135 +0.0035 (+0.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 33,787
Open 0.6201
Bid (Size) 0.6135 (18)
Ask (Size) 0.6800 (25)
Prev. Close 0.6100
Today's Range 0.6000 - 0.6500
52wk Range 0.5009 - 4.740
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA
Via ACCESSWIRE
PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
PTPI stock results show that Petros Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-56.80%
-56.80%
1 Month
-3.29%
-3.29%
3 Month
-62.82%
-62.82%
6 Month
-51.76%
-51.76%
1 Year
-76.49%
-76.49%

More News

Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
From 23andMe, Inc.
Via GlobeNewswire
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
Via ACCESSWIRE
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
Via ACCESSWIRE
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch
Via ACCESSWIRE
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
Via ACCESSWIRE
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
Via ACCESSWIRE
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider
Via ACCESSWIRE
PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
Via ACCESSWIRE
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
Via ACCESSWIRE
BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc
Via TheNewswire.com
Exposures Product Safety
BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc
Via News Direct
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch
Via ACCESSWIRE
Why ReShape Lifesciences Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Exposures Product Safety
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.